RESUMO
A double-blind, placebo-controlled randomized design was employed to test the efficacy and optimal dosage of Suloctidil in the treatment of primary degenerative dementia (PDD i.e., Alzheimer's disease). Initially, 30 geriatric patients with a diagnosis of PDD were matched for age, education, and handedness, and randomly assigned to one of three groups: (a) 600 mg. Suloctidil daily; (b) 450 mg. Suloctidil daily; (c) or placebo, for 12 weeks. All patients were administered individually a brief neuropsychological battery at pretreatment and at 12-week posttreatment. The tests were the Boston Naming Test, the Thurstone Word Fluency Test, the Trail Making Test, and the Grooved Pegboard. While there was differential attrition across the three groups, the results of the Boston Naming Test suggest a medication-dosage effect.
